Zydus Cadila gets tentative FDA nod for generic Otezla

Press enter to search
Close search
Open Menu

Zydus Cadila gets tentative FDA nod for generic Otezla

By Sandra Levy - 11/19/2019

Zydus Cadila has received the Food and Drug Administration’s tentative nod for apremilast tablets, a generic of Celgene's Otezla. The product has been tentatively approved in dosage strengths of 10 mg, 20 mg, and 30 mg. 

Apremilast tablets are used to treat psoriatic arthritis. They also are used to treat mouth sores in people who have Behcet's disease.

The tablets will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

 

 

RELATED TOPICS